Trial · NCT00105027
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
NCT00105027, Phase 3, Completed, The Emmes Company, LLC; results first posted 2011-01-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study. Trials, record NCT00105027. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00105027
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
- NCT number
- NCT00105027
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 682 participants, actual
- Lead sponsor
- The Emmes Company, LLC
- Conditions
- Macular Edema, Cystoid, Retinal Vein Occlusion
- Interventions
- Standard Care, intravitreal triamcinolone injection, intravitreal triamcinolone injection
- First posted
- 2005-03-04
- Last updated
- 2018-07-02
- Results first posted
- 2011-01-19
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | Change from baseline to 12 months | Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart. |
| Secondary | Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | 12 months | |
| Secondary | Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | 12 months | |
| Secondary | Adverse Ocular Outcomes | 12 months |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | Change from baseline to 12 months | Participants | NUMBER | |
| SECONDARY | Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | 12 months | Participants who attended month 12 visit | letters read | MEAN |
| SECONDARY | Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography | 12 months | Participants who attended month 12 visit | um | MEDIAN |
| SECONDARY | Adverse Ocular Outcomes | 12 months | Participants experiencing an adverse event | events | NUMBER |
Source ClinicalTrials.gov
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | CRVO Observation | 5 | Participants | ||
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | CRVO 1 mg Dose Triamcinolone Acetonide | 22 | -6.4 to 4.1 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | CRVO 4 mg Dose Triamcinolone Acetonide | 21 | -6.3 to 4.0 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | BRVO Standard Care | 35 | 1.1 to 7.3 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | BRVO 1 mg Dose Triamcinolone Acetonide | 31 | 2.8 to 8.6 | Participants | |
| The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit | BRVO 4 mg Dose Triamcinolone Acetonide | 34 | 0.9 to 7.2 | Participants | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | CRVO Observation | -12.1 | 95% Confidence Interval -17.1 to -7.1 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | CRVO 1 mg Dose Triamcinolone Acetonide | -1.2 | 95% Confidence Interval -6.4 to 4.1 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | CRVO 4 mg Dose Triamcinolone Acetonide | -1.2 | 95% Confidence Interval -6.3 to 4.0 | letters read | |
| Changes From Baseline in Best-corrected ETDRS Visual Acuity Score | BRVO Standard Care | 4.2 | 95% Confidence Interval 1.1 to 7.3 | letters read |
1 to 10 of 120Source ClinicalTrials.gov
See all 120 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CRVO Observation | 88 | |
| Overall Study | STARTED | CRVO 1 mg Dose Triamcinolone Acetonide | 92 | |
| Overall Study | STARTED | CRVO 4 mg Dose Triamcinolone Acetonide | 91 | |
| Overall Study | STARTED | BRVO Standard Care | 137 | |
| Overall Study | STARTED | BRVO 1 mg Dose Triamcinolone Acetonide | 136 | |
| Overall Study | STARTED | BRVO 4 mg Dose Triamcinolone Acetonide | 138 | |
| Overall Study | COMPLETED | CRVO Observation | 73 | |
| Overall Study | COMPLETED | CRVO 1 mg Dose Triamcinolone Acetonide | 83 | |
| Overall Study | COMPLETED | CRVO 4 mg Dose Triamcinolone Acetonide | 82 | |
| Overall Study | COMPLETED | BRVO Standard Care | 121 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events1,452
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blepharitis | Eye disorders | CRVO Observation | 0 | 88 | 0 |
| other | Blepharitis | Eye disorders | CRVO 1 mg Dose Triamcinolone Acetonide | 3 | 92 | 5 |
| other | Blepharitis | Eye disorders | CRVO 4 mg Dose Triamcinolone Acetonide | 8 | 91 | 19 |
| other | Blepharitis | Eye disorders | BRVO Standard Care | 4 | 137 | 8 |
| other | Blepharitis | Eye disorders | BRVO 1 mg Dose Triamcinolone Acetonide | 9 | 136 | 16 |
| other | Blepharitis | Eye disorders | BRVO 4 mg Dose Triamcinolone Acetonide | 6 | 138 | 11 |
| other | Bronchitis | Infections and infestations | CRVO Observation | 1 | 88 | 1 |
| other | Bronchitis | Infections and infestations | CRVO 1 mg Dose Triamcinolone Acetonide | 3 | 92 | 4 |
| other | Bronchitis | Infections and infestations | CRVO 4 mg Dose Triamcinolone Acetonide | 5 | 91 | 6 |
| other | Bronchitis | Infections and infestations | BRVO Standard Care | 5 | 137 | 6 |
1 to 10 of 1,452Source ClinicalTrials.gov
See all 1,452 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CRVO Observation | 0 | 88 |
| Total, all-cause mortality | CRVO 1 mg Dose Triamcinolone Acetonide | 1 | 92 |
| Total, all-cause mortality | CRVO 4 mg Dose Triamcinolone Acetonide | 2 | 91 |
| Total, all-cause mortality | BRVO Standard Care | 3 | 137 |
| Total, all-cause mortality | BRVO 1 mg Dose Triamcinolone Acetonide | 2 | 136 |
| Total, all-cause mortality | BRVO 4 mg Dose Triamcinolone Acetonide | 2 | 138 |
| Total, other adverse events | CRVO Observation | 76 | 88 |
| Total, other adverse events | CRVO 1 mg Dose Triamcinolone Acetonide | 87 | 92 |
| Total, other adverse events | CRVO 4 mg Dose Triamcinolone Acetonide | 89 | 91 |
| Total, other adverse events | BRVO Standard Care | 118 | 137 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers15
The papers the trial lists on ClinicalTrials.gov.
Grants3
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| U10EY014351 | The Intravitreal Corticosteroid for Macular Edema Study | IP, MICHAEL S | UNIVERSITY OF WISCONSIN-MADISON | NATIONAL EYE INSTITUTE | 2003 to 2008 | NIH RePORTER |
| U10EY014352 | Intravitreal Corticosteroid for Macular Edema Study | BLODI, BARBARA A | UNIVERSITY OF WISCONSIN-MADISON | NATIONAL EYE INSTITUTE | 2003 to 2008 | NIH RePORTER |
| U10EY014404 | Intravitreal Corticosteroid for Macular Edema | VAN VELDHUISEN, PAUL C | THE EMMES COMPANY, LLC | NATIONAL EYE INSTITUTE | 2003 to 2008 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00105027
GET https://conductscience.org/api/trials/v1/NCT00105027/results?page=2